

Invitation to webcast with CEO and Chairman of the Board: company update with regards to CEO-change, Q2 report and goodwill impairment

BICO communicated on Monday evening, among other things, that CEO and President Erik Gatenholm later this Autumn will hand over the CEO position to externally recruited Maria Forss. BICO invites you to a digital investor meeting, today on August 22, at 17:45 CEST, with the company's CEO Erik Gatenholm and Rolf Classon, Chairman of the board.

The webcast will address:

- Information about the leadership change
- Brief presentation of newly appointed president and CEO Maria Forss
- The goodwill impairment
- Brief update of the Q2 report

Jacob Thordenberg, CFO, also participates in the Webcast.

After the presentation, which is expected to last around 15 minutes, there will also be an opportunity to ask questions to the company's representatives.

Link to the webcast: <https://www.finwire.tv/webcast/bico-group/presentation/>

For further information, please contact:

Erik Gatenholm, President & CEO, BICO Group AB
Telephone US: +1 (650) 515-5566
Telephone Sweden: +46 73 267 00 00
E-mail: eg@bico.com

Jacob Thordenberg, Chief Financial Officer, BICO Group AB
Phone: +46 73 534 88 84
E-mail: jt@bico.com

The information was submitted for publication, through the agency of the contact person set out above, on August 22, 2023 at 07:30am CEST.

If you wish to send questions to the company update, please contact:

BICO Investor Relations:
Phone: +46 735 46 57 77
E-mail: ir@bico.com

About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments

[Invitation to webcast with CEO and Chairman of the Board: company update with regards to CEO-change, Q2 report and goodwill impairment](#)